Zentalis Pharmaceuticals, Inc. Weighted Average Number of Shares Outstanding, Basic and Diluted
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 40.36 million shares for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-17.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2021-05-17
- Zentalis Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-03-31 was 40.36M shares, a 620.57% increase year-over-year.
- Zentalis Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-12-31 was 39.94M shares, a 615.06% increase year-over-year.
- Zentalis Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-09-30 was 37.96M shares, a 577.72% increase year-over-year.
- Zentalis Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-06-30 was 34.35M shares, a 513.34% increase year-over-year.
- Zentalis Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 28.11M shares, a 402.29% increase from fiscal 2019.
- Zentalis Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 5.60M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2021-03-31 | 40.36M shares 10-Q · filed 2021-05-17 | 40.15M shares derived: average of 2 quarters · filed 2021-05-17 | 39.42M shares derived: average of 3 quarters · filed 2021-05-17 | 38.15M shares derived: average of 4 quarters · filed 2021-05-17 |
| 2020-12-31 | 39.94M shares 10-K · filed 2021-03-25 | 38.95M shares derived: average of 2 quarters · filed 2021-03-25 | 37.42M shares derived: average of 3 quarters · filed 2021-03-25 | 28.11M shares 10-K · filed 2021-03-25 |
| 2020-09-30 | 37.96M shares 10-K · filed 2021-03-25 | 36.16M shares derived: average of 2 quarters · filed 2021-03-25 | 24.14M shares 10-Q · filed 2020-11-09 | 20.87M shares derived: average of 4 quarters · filed 2021-05-17 |
| 2020-06-30 | 34.35M shares 10-K · filed 2021-03-25 | 16.98M shares 10-Q · filed 2020-08-13 | 15.18M shares derived: average of 3 quarters · filed 2021-05-17 | 12.79M shares derived: average of 4 quarters · filed 2021-05-17 |
| 2020-03-31 | 5.60M shares 10-Q · filed 2021-05-17 | 5.59M shares derived: average of 2 quarters · filed 2021-05-17 | 5.60M shares derived: average of 3 quarters · filed 2021-05-17 | 5.60M shares derived: average of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | 5.58M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | 5.59M shares derived: average of 2 quarters · filed 2021-03-25 | 5.60M shares derived: average of 3 quarters · filed 2021-03-25 | 5.60M shares 10-K · filed 2021-03-25 |
| 2019-09-30 | 5.60M shares 10-Q · filed 2020-11-09 | 5.60M shares derived: average of 2 quarters · filed 2020-11-09 | 5.60M shares 10-Q · filed 2020-11-09 | |
| 2019-06-30 | 5.60M shares 10-Q · filed 2020-08-13 | 5.60M shares 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | 5.59M shares 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |